Tred Avon Family Wealth LLC Makes New $1.18 Million Investment in Stryker Corporation $SYK

Tred Avon Family Wealth LLC acquired a new stake in Stryker Corporation (NYSE:SYK) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 3,188 shares of the medical technology company’s stock, valued at approximately $1,179,000.

Other hedge funds also recently made changes to their positions in the company. Resonant Capital Advisors LLC increased its holdings in Stryker by 1.7% during the third quarter. Resonant Capital Advisors LLC now owns 9,770 shares of the medical technology company’s stock worth $3,620,000 after buying an additional 167 shares during the last quarter. Lmcg Investments LLC increased its stake in shares of Stryker by 407.6% during the 3rd quarter. Lmcg Investments LLC now owns 11,015 shares of the medical technology company’s stock worth $4,072,000 after purchasing an additional 8,845 shares during the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of Stryker by 2.6% in the 3rd quarter. Maryland State Retirement & Pension System now owns 17,163 shares of the medical technology company’s stock worth $6,345,000 after purchasing an additional 433 shares during the period. Sequoia Financial Advisors LLC lifted its stake in Stryker by 0.5% in the third quarter. Sequoia Financial Advisors LLC now owns 13,031 shares of the medical technology company’s stock valued at $4,817,000 after purchasing an additional 69 shares during the last quarter. Finally, Occidental Asset Management LLC grew its holdings in Stryker by 179.6% during the third quarter. Occidental Asset Management LLC now owns 2,335 shares of the medical technology company’s stock valued at $863,000 after purchasing an additional 1,500 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 522,118 shares of company stock worth $185,381,932. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $364.45 on Friday. The company’s 50 day simple moving average is $360.20 and its two-hundred day simple moving average is $373.92. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The stock has a market capitalization of $139.38 billion, a PE ratio of 47.89, a P/E/G ratio of 2.33 and a beta of 0.89.

Stryker (NYSE:SYK) last released its quarterly earnings results on Friday, October 31st. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.87 earnings per share. Analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s payout ratio is presently 46.25%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SYK. UBS Group set a $408.00 target price on Stryker in a research note on Monday, October 13th. Citizens Jmp upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price objective on the stock in a research note on Friday, December 19th. Truist Financial cut their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research report on Thursday, December 18th. BTIG Research reissued a “buy” rating and issued a $410.00 price target on shares of Stryker in a research report on Friday, November 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $448.00 price objective on shares of Stryker in a report on Friday, November 14th. Fourteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $430.00.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.